e-learning
resources
Paris 2018
Sunday, 16.09.2018
Pharmacological management of COPD
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Switch from LABA+ICS to a LABA/LAMA combination in symptomatic women with COPD – an analysis of the observational DACCORD study
P. Kardos (Frankfurt, Germany), R. Buhl (Mainz, Germany), C. Criee (Bovenden , Germany), N. Lossi (Nuernberg, Germany), C. Vogelmeier (Marburg, Germany), H. Worth (Fuerth, Germany)
Source:
International Congress 2018 – Pharmacological management of COPD
Session:
Pharmacological management of COPD
Session type:
Thematic Poster
Number:
780
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
P. Kardos (Frankfurt, Germany), R. Buhl (Mainz, Germany), C. Criee (Bovenden , Germany), N. Lossi (Nuernberg, Germany), C. Vogelmeier (Marburg, Germany), H. Worth (Fuerth, Germany). Switch from LABA+ICS to a LABA/LAMA combination in symptomatic women with COPD – an analysis of the observational DACCORD study. 780
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Effectiveness of combination therapy with tiotropium in COPD. A secondary analysis of the UPLIFT trial
Source: Annual Congress 2009 - Functional insights into COPD
Year: 2009
Exacerbation outcomes with LAMA/LABA and ICS/LABA in high risk COPD patients in the IMPACT trial
Source: International Congress 2018 – COPD management
Year: 2018
A novel study design for the comparison between once-daily QVA149 and twice-daily salmeterol/fluticasone on the reduction of COPD exacerbations: The FLAME study
Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics
Year: 2013
Efficacy and safety of QVA149 compared with salmeterol/fluticasone combination (SFC) in Chinese patients with moderate-to-severe COPD: A subgroup analysis from the LANTERN study
Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD
Year: 2015
Once-daily QVA149 demonstrates superior outcomes in COPD patients previously treated with fixed-dose long-acting beta
2
-agonist/inhaled corticosteroid (LABA/ICS): The ILLUMINATE study
Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings
Year: 2013
Overall and cardiovascular safety of aclidinium/formoterol fixed-dose combination versus salmeterol/fluticasone in patients with COPD
Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD
Year: 2015
Effect of triple therapy with extra-fine BDP/FF/GB pMDI vs non-triple maintenance therapies on severe COPD exacerbations. A pooled analysis of the TRILOGY, TRINITY and TRIBUTE studies.
Source: Virtual Congress 2020 – Clinical studies of COPD: combination inhalers and much more
Year: 2020
COPD patients continuing salmeterol or switched to tiotropium: a retrospective analysis of clinical trial data
Source: Eur Respir J 2007; 30: Suppl. 51, 612s
Year: 2007
Late Breaking Abstract - A randomized clinical study to assess the impact of budesonide/formoterol (BUD/FM) pMDI medication reminders on adherence in COPD patients
Source: International Congress 2018 – Integrating pharmacological and non-pharmacological management in COPD: are we there yet?
Year: 2018
Budesonide/formoterol as maintenance and reliever therapy in uncontrolled asthma compared with high dose salmeterol/fluticasone: the AHEAD double-blind study
Source: Annual Congress 2007 - Recent advances in our understanding of the mechanisms of asthma treatment
Year: 2007
Efficacy and safety of single-inhaler triple therapy of glycopyrronium, formoterol and fluticasone in patients with COPD: a double-blind, randomised controlled trial
Source: ERJ Open Res, 7 (3) 00255-2021; 10.1183/23120541.00255-2021
Year: 2021
Once-daily NVA237 reduces exacerbations and improves symptoms in COPD patients: A pooled analysis of the GLOW1 and GLOW2 studies
Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights
Year: 2012
LABA/LAMA combination in COPD: a meta-analysis on the duration of treatment
Source: Eur Respir Rev 2017; 26: 160043
Year: 2017
Efficacy of aclidinium/formoterol fixed-dose combination versus salmeterol/fluticasone in COPD
Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis
Year: 2015
Efficacy and safety of once-daily low-dose indacaterol/mometasone via Breezhaler® in symptomatic adult and adolescent patients with inadequately controlled asthma: Phase III randomised QUARTZ study findings
Source: International Congress 2019 – ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: Asthma
Year: 2019
Efficacy and safety of as-needed corticosteroid plus fast or short-acting beta-agonists monotherapy in patients with mild asthma: a meta-analysis of randomised controlled trials.
Source: Virtual Congress 2020 – Inhaled corticosteroids and bronchodilator studies in asthma
Year: 2020
INTREPID study: Once-daily single-inhaler fluticasone furoate/umeclidinium/vilanterol vs multiple-inhaler triple therapy; sub-analysis by prior medication strata
Source: Virtual Congress 2020 – Clinical studies of COPD: combination inhalers and much more
Year: 2020
Tiotropium discontinuation in patients with early-stage COPD: a prospective observational cohort study
Source: ERJ Open Res, 5 (1) 00175-2018; 10.1183/23120541.00175-2018
Year: 2019
The use of high-dose inhaled corticosteroids and add-on therapy in children in the UK: an observational study of 4332 patients
Source: Annual Congress 2004 - New aspects of drug therapy in paediatric asthma
Year: 2004
Efficacy of tiotropium and olodaterol fixed-dose combination in patients with COPD on β-blockers
Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept